SLC5A2 and peripheral arterial disease: After a brief presentation of both the pathophysiology of DF and the pharmacology of this promising anti-diabetic oral agent, we will subsequently discuss the effect of SGLT2-i on the multifaceted components of diabetic foot, such as the immunomodulatory effect on the vascular system, neuropathy, peripheral artery disease, risk of infection, and risk of amputation.